Meeting
2023 ASCO Annual Meeting
Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).
Authors
Wen Wee Ma
Division of Medical Oncology, Mayo Clinic, Rochester, MN
Wen Wee Ma , Anthony W. Tolcher , Cesar Augusto Perez , Douglas Orr , Erika P. Hamilton , Yujie Zhao , Yonina R. Murciano-Goroff , Carey K. Anders , Gregory Paul Adams , Catherine W. Reddick , Eliel Bayever
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05001282
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3159)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3159
Abstract #
TPS3159
Poster Bd #
354a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
ELU-FRα-1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα).
First Author: Wen Wee Ma
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin
Poster
2020 ASCO Virtual Scientific Program
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
First Author: David S. Hong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
First Author: Aparna Raj Parikh